Evaluation of anticancer therapy- related dermatologic adverse events: insights from fda's faers dataset

Evaluation of anticancer therapy- related dermatologic adverse events: insights from fda's faers dataset

Saved in:

Bibliographic Details
Main Authors:	S. Salah, D. Kerob, C. Pages Laurent, M. Lacouture, V. Sibaud
Format:	Article
Language:	English
Published:	Elsevier 2024-01-01
Series:	EJC Skin Cancer
Online Access:	http://www.sciencedirect.com/science/article/pii/S2772611824001873
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database
by: Yuan-Yuan Wu, et al.
Published: (2025-05-01)

Ophthalmic corticosteroids-related adverse events: the FDA adverse event reporting system (FAERS) database pharmacovigilance study
by: Chengzhi Liu, et al.
Published: (2024-12-01)

Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
by: Chang-Zhu He, et al.
Published: (2025-03-01)

A disproportionality analysis of FDA adverse event reporting system (FAERS) events for methimazole and propylthiouracil
by: Yun Li, et al.
Published: (2025-01-01)

Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
by: Weidong Zhang, et al.
Published: (2025-01-01)

Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
by: Zhuomiao Lin, et al.
Published: (2025-08-01)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for lecanemab
by: Linlin Yan, et al.
Published: (2025-04-01)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for avatrombopag
by: Zhong Xue, et al.
Published: (2024-11-01)

Hepatobiliary Adverse Events Associated with Pembrolizumab: A Pharmacovigilance Study from the FDA Adverse Event Reporting System (FAERS) Database
by: Connor Frey
Published: (2024-12-01)

Real-world safety assessment of Ixekizumab based on the FDA Adverse Event Reporting System (FAERS)
by: Yuzhe Cheng, et al.
Published: (2025-01-01)

Real-world safety assessment of Ixekizumab based on the FDA Adverse Event Reporting System (FAERS).
by: Yuzhe Cheng, et al.
Published: (2025-01-01)

A real-world pharmacovigilance analysis of omadacycline in FDA adverse event reporting system (FAERS) database
by: Xueping Shi, et al.
Published: (2025-04-01)

A real-world data analysis of montelukast in FDA Adverse Event Reporting System (FAERS) database
by: Hesen Huang, et al.
Published: (2025-07-01)

A real-world pharmacovigilance study of netarsudil based on the FDA adverse event reporting system (FAERS)
by: Xiaomei Xiong, et al.
Published: (2025-04-01)

Disproportionality analysis of adverse events associated with pacritinib: a real-world study based on FDA Adverse Event Reporting System (FAERS) database
by: Huiling Zhang, et al.
Published: (2025-07-01)

Disproportionality analysis of vibegron-associated adverse events using the FDA adverse event reporting system (FAERS): a real-world pharmacovigilance study
by: Bangbei Wan, et al.
Published: (2025-02-01)

Descriptive Analysis of Reported Adverse Events Associated with Vitiligo Medications Using FDA Adverse Event Reporting System (FAERS) Databases 2013–2023
by: Saleh F. Alqifari, et al.
Published: (2025-07-01)

Chloroquine and hydroxychloroquine-related ocular adverse events in SLE treatment: a real-world disproportionality analysis based on FDA adverse event reporting system (FAERS)
by: Xiang Li, et al.
Published: (2025-06-01)

Tirzepatide safety in type 2 diabetes: a disproportionality analysis of adverse events using the FDA FAERS database
by: Zhenpo Zhang, et al.
Published: (2025-07-01)

A Real-World Data Analysis of Alglucosidase Alfa in the FDA Adverse Event Reporting System (FAERS) Database
by: Yi Yin, et al.
Published: (2025-01-01)

Exploring Ototoxicity Associated with Capmatinib: Insights from a Real-World Data Analysis of the FDA Adverse Event Reporting System (FAERS) Database
by: Lin Y, et al.
Published: (2025-06-01)

Multidimensional assessment of adverse events of finasteride：a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024.
by: Xiaoling Zhong, et al.
Published: (2025-01-01)

Drug-induced pulmonary edema: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS)
by: Zilan Zhong, et al.
Published: (2025-08-01)

A real-world disproportionality analysis of Tenofovir Alafenamide (TAF): Data mining of the FDA adverse event reporting system (FAERS)
by: Chao Zhang, et al.
Published: (2025-01-01)

Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system (FAERS) database
by: Yamin Shu, et al.
Published: (2023-02-01)

Hematologic and lymphatic disorders associated with chimeric antigen receptor T-cell therapy: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database
by: Zhenpo Zhang, et al.
Published: (2025-05-01)

Real-world study of adverse events associated with triptan use in migraine treatment based on the U.S. Food and Drug Administration (FDA) adverse event reporting system (FAERS) database
by: Wen-Hui Liu, et al.
Published: (2024-11-01)

A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS)
by: Ning Wang, et al.
Published: (2024-12-01)

Understanding the Opioid Epidemic through Pharmacovigilance Signals: an Analysis of Pharmacovigilance Datasets collecting Adverse Drug Reactions (ADRs) reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS) over 10 Years
by: S. Chiappini, et al.
Published: (2024-12-01)

Immune-mediated enterocolitis is associated with immune checkpoint inhibitors: A pharmacovigilance study from the FDA Adverse Event Reporting System (FAERS) database
by: Connor Frey
Published: (2025-01-01)

Disproportionate adverse event signals of selumetinib in neurofibromatosis type I: insights from FAERS
by: Lin Li
Published: (2025-01-01)

Gender differences in drug-induced precocious puberty: a real-world analysis of adverse event reports from the FDA FAERS database (2004–2024)
by: Bangguo Song, et al.
Published: (2025-07-01)

Real-World Safety Profile of Proton Pump Inhibitors in Infants as Reported in the FDA Adverse Event Reporting System (FAERS): Tiny Tummies, Key Decisions
by: Hülya Tezel Yalçın, et al.
Published: (2025-05-01)

Analysis and mining of Dupilumab adverse events based on FAERS database
by: Hui Gao, et al.
Published: (2025-03-01)

Analysis and mining of brodalumab adverse events based on FAERS database
by: Yue Wan, et al.
Published: (2025-05-01)

Updated insights into adverse events associated with mepolizumab: a disproportionality analysis from the FDA adverse event reporting system database
by: Shan Lin, et al.
Published: (2024-10-01)

Disproportionality analysis of adverse events associated with ipilimumab and nivolumab combination therapy based on FAERS database
by: Xianyu Dai, et al.
Published: (2025-07-01)

Adverse events associated with Implantable Collamer Lens: insights from the FDA MAUDE database
by: Qing Chen, et al.
Published: (2025-07-01)

Signal mining and risk analysis of olanzapine adverse events in the FAERS database
by: Aiguo Dong, et al.
Published: (2025-07-01)

Analysis of postmarketing neuropsychiatric adverse events of avapritinib based on the FDA adverse event reporting system
by: Wei Mao, et al.
Published: (2025-01-01)